Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Hercules Capital, Inc.

Investor type Venture Debt
Founders Manuel A. Henriquez Roy Y. Liu Scott Harvey

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 219
Average round size
info
The average size of a deal this fund participated in
$22M
Portfolio companies 196
Rounds per year 11.53
Lead investments 60
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 130
Key employees 5
Stages of investment
Debt

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Software
Summary

In 2003 was created Hercules Capital, Inc., which is appeared as VC. The main department of described VC is located in the Palo Alto. The company was established in North America in United States.

The current fund was established by Manuel A. Henriquez, Scott Harvey. Besides them, we counted 5 critical employees of this fund in our database.

The higher amount of exits for fund were in 2010. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Hercules Capital, Inc. performs on 24 percentage points more the average number of lead investments. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 7-12 deals per year.

Among the most successful fund investment fields, there are Medical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Anacor Pharmaceutical, Machine Zone, Zayo. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Hercules Capital, Inc., startups are often financed by VantagePoint Capital Partners, OrbiMed, InterWest Partners. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Venrock, Kleiner Perkins. In the next rounds fund is usually obtained by Venrock, Steamboat Ventures, General Motors Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Hercules Capital, Inc.:
Typical Co-investors
Hercules Capital, Inc. is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Hercules Capital, Inc.:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Benxi Steel Benxi, China, Liaoning
Clearvision Ventures California, Menlo Park, United States
Eterna Capital England, London, United Kingdom
Exnetwork Capital -
Gabriel Investments Pennsylvania, Philadelphia, United States
GuarantCo -
Hainan Huantai Equity Investment Fund Management China, Hainan, Hainan Province
Jennison Associates New York, New York, United States
Long Pinxi Capital -
LW Investment Management -
Meritage Funds Colorado, Denver, United States
Novelion Therapeutics British Columbia, Canada, Vancouver
Park House Ventures Cornwall, Truro, United Kingdom
Shalamuka Capital Gauteng, NA - South Africa, South Africa
Suzhou International Development Venture Capital China, Jiangsu, Suzhou
TAG Capital Arizona, Fountain Hills, United States
TrueBridge Capital Partners Chapel Hill, North Carolina, United States
Wutongshu Capital -
Zimi Fund China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Oak Street Health

Health Care
Hospital
Medical
$300M16 Nov 2022 Chicago, Illinois, United States

Kura Oncology

Biopharma
Biotechnology
Genetics
Health Care
Medical
$125M03 Nov 2022 San Diego, California, United States

Phathom Pharmaceuticals

Biotechnology
Pharmaceutical
$40M01 Nov 2022 Alaska, United States

Bright Machines

Computer
Information Technology
Machine Learning
Manufacturing
Robotics
Software
$32M31 Oct 2022 San Francisco, California, United States

Tricida

Health Care
Medical
Pharmaceutical
$125M19 Oct 2022 California, United States

Replimune Group

Biotechnology
Health Care
Medical
Therapeutics
$200M10 Oct 2022 Woburn, Massachusetts, United States

Automation Anywhere

Artificial Intelligence
Data Center Automation
Enterprise
Enterprise Software
Human Resources
Industrial Automation
Information Technology
Machine Learning
Robotics
SaaS
Software
$200M03 Oct 2022 San Jose, California, United States

Provention Bio

Biotechnology
Health Care
Medical
Pharmaceutical
$125M31 Aug 2022 New Jersey, United States

Alladapt Immunotherapeutics

Biotechnology
$50M30 Aug 2022 California, United States
News
HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital

– HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
– The company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
– The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
– Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate also participated in the round.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hercules Capital, Inc.?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: